Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5603398 | 0.84 | KMT2A (0.60) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL2790377 | 0.83 | TSHR (0.56) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL11796135 | 0.82 | AOC2 (0.66) | KMT2AMEN1HTTCYP1A2GAA | |
| SCHEMBL990297 | 0.82 | ALDH1A1 (0.60) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL4167897 | 0.80 | KMT2A (0.54) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL1821575 | 0.80 | ALDH1A1 (0.61) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL8770332 | 0.80 | TSHR (0.53) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL6048516 | 0.80 | KMT2A (0.58) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL2673969 | 0.79 | LOXL2 (0.59) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL5067751 | 0.79 | ALDH1A1 (0.57) | KMT2AALDH1A1MEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655536-A | Class N 1 -aryl-3-fluoroalkyl-5-fluoropyrazole compound, and preparation method and application thereof | 天津大学 | 2023-08-29 | — | — | CN | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-03-04 | — | — | US | disclosed |
| CN-1474820-A | Benzodiazepine derivatives as GABA A receptor modulators | - | 2004-02-11 | — | — | CN | disclosed |
| EP-1337535-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| EP-0749433-B1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | SYNGENTA LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002040487-A2 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
| US-5952359-A | NEMATICIDES, INSECTICIDES AND MITICIDES; 1,1-DIFLUORO-3-(THIAZOLYL OR ISOTHIAZOYL-THIO (OR SULFINYL OR SULFONYL)-PROP-1-ENE DERIVATIVES | ZENECA LIMITED (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5912243-A | NOVEL COMPOUNDS FOR CONTROLLING NEMATODES, INSECT OR ACARID PESTS | ZENECA LIMITED (GB) | 1999-06-15 | — | — | US | disclosed |
| US-5705516-A | NEMATOCIDES, INSECTICIDES, ACARICIDES | ZENECA LIMITED (GB) | 1998-01-06 | — | — | US | disclosed |
| EP-0749433-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024403-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | KMT2A 1267/4885ALDH1A1 278/4885MEN1 3485/4885 |
| US-20100056507-A1 | PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT | CNR2, CNR1, TRPV1 | KMT2A 2065/4885ALDH1A1 2439/4885MEN1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.